TY  - JOUR
PY  - 2023//
TI  - A phase 1b, double blind, randomized study of cannabis oil for pain in Parkinson's disease
JO  - Movement disorders clinical practice
A1  - Di Luca, D.G.
A1  - Gilmour, G.S.
A1  - Fearon, C.
A1  - Swinkin, E.
A1  - Freitas, E.
A1  - Kuhlman, G.
A1  - Fox, S.H.
A1  - Mestre, T.
SP  - 1114
EP  - 1119
VL  - 10
IS  - 7
N2  - BACKGROUND: Pain is common in Parkinson's disease (PD), but effective therapies are limited. <br><br>OBJECTIVES: To determine the maximum tolerated dose (MTD) and safety of formulations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) for pain in PD. <br><br>METHODS: In this phase 1b, double-blind, randomized, single-center study, participants were randomized to three formulations of THC/CBD (18:0, 10:10, and 1:20). The MTD, adverse events (AE), and tolerability are described for each formulation. <br><br>RESULTS: Eight participants were randomized. The MTD was similar among groups (0.8-0.9 mL/daily), and there were no serious AE or study drop-outs. The most common AE were drowsiness and dizziness (three participants). Epworth sleepiness scale scores were higher in the high CBD formulation (1:20). <br><br>CONCLUSIONS: In patients with pain and PD, mixed formulations of THC/CBD were tolerated with no serious AE. Considering the safety profile, future phase II studies should be considered. © 2023 International Parkinson and Movement Disorder Society.<p />  <p>Language: en</p>
LA  - en
SN  - 2330-1619
UR  - http://dx.doi.org/10.1002/mdc3.13754
ID  - ref1
ER  -